



IBA to Install New Proteus®ONE Proton Therapy System in Taiwan

Second contract signed with Tomorrow Medical Systems Co. Ltd.

Louvain-la-Neuve, Belgium, December 21st, 2015 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it has signed a contract with TMS (Tomorrow Medical Systems Co. Ltd.) for the installation of its single-room proton therapy system *Proteus®ONE** in Taiwan.

The contract signed in Taipei, includes the delivery of the *Proteus®ONE* equipment as well a long term service and maintenance agreement which together represents a value between EUR 30 to 35 million to IBA. This is the second contract signed with TMS for an installation of a proton therapy center in Taiwan. The first one was signed in 2013.

TMS is part of the CHC Healthcare Group (CHC), listed on the Taipei stock exchange. TMS operates radiotherapy services for a number of medical centers in Taiwan.

The *Proteus®ONE* system has been developed by IBA to allow more patients globally to access proton therapy. *Proteus®ONE* is a smaller, less expensive and faster to install proton therapy solution, encompassing the latest in proton therapy technologies, including Pencil Beam Scanning.

Olivier Legrain, Chief Executive Officer of IBA, commented: *“This new contract demonstrates IBA’s continued success in Asia. Making proton therapy smaller and more affordable, without jeopardizing cutting edge technology, is one of IBA’s key strategic goals and the Proteus®ONE system does exactly that whilst continuing to provide the most accurate form of radiation therapy available. We look forward to continue working with our local partners in Taiwan to provide patients across the region with access to the benefits of proton therapy.”*

Pei-lin Lee, President of CHC Group: *“CHC is very happy to partner with IBA to install a second Proteus®ONE system in Taiwan. Proteus®ONE allows patients to be treated with Intensity Modulated Proton Therapy using Pencil Beam Scanning Technology which will greatly benefit cancer patients in Taiwan.”*

end

About Proteus®ONE

Proteus®ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. *Proteus®ONE* is smaller, more affordable, easier to install and to operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide. *Proteus®ONE* makes Proton Therapy easy.



About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1200 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

** Proteus®ONE is the brand name of a new configuration of the Proteus®235*

About CHC

CHC Healthcare Group (CHC) is a leading Taiwan full healthcare service solution provider for high-end radiation therapy, radiology, neurosurgery, ophthalmology and dentistry equipment. Since 2009, CHC installations of radiotherapy equipment have accounted for 80% of the total Taiwanese market. CHC is the exclusive master distributor for a portfolio of global brand names and has over 60+ certified experienced service engineers providing world class after sales support and maintenance services. Website: www.cyhc.com.tw

For further information please contact:

IBA

Jean-Marc Bothy
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
Communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
IBA@consilium-comms.com

Rx Communications Group (US)

Melody Carey
+ 1 917 322 2571
mcarey@RxIR.com